Amanda R Vest1, Stanley M Mistak2, Rory Hachamovitch3, Maria M Mountis4, Nader Moazami4, James B Young5. 1. Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio; Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: avest@tuftsmedicalcenter.org. 2. Transplantation Center, Cleveland Clinic, Cleveland, Ohio. 3. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. 4. Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio; Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. 5. Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio; Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: Diabetes mellitus (DM) is a risk factor for mortality among patients with heart failure as well as for patients who undergo cardiothoracic surgery. However it is unknown whether DM is associated with increased mortality or major complications during continuous-flow left ventricular assist device (CF-LVAD) support. METHODS AND RESULTS: We retrospectively reviewed 300 consecutive adults who received CF-LVADs at a single center in the years 2006-2013; 129 patients had DM before LVAD, as defined by American Diabetes Association criteria (HbA1c ≥6.5% and/or taking DM medications). Compared with the non-DM group, DM patients were older, with a higher pre-LVAD body mass index, more ischemic heart failure etiology, and higher pre-LVAD creatinine. Ninety-three patients died on LVAD support, 43 with DM and 50 without DM (P = .4526). After control for 9 covariates in a Cox proportional hazards model, DM was unassociated with all-cause mortality (hazard ratio 0.883, 95% confidence interval 0.571-1.366; P = .5768). Diabetes was also unassociated with the adverse event end points of stroke/transient ischemic attack, intracerebral hemorrhage, pump thrombosis, and device-related infections. CONCLUSIONS: Diabetes is common in LVAD recipients (43% of the present cohort) but does not increase mortality or rates of major adverse events during CF-LVAD support.
BACKGROUND:Diabetes mellitus (DM) is a risk factor for mortality among patients with heart failure as well as for patients who undergo cardiothoracic surgery. However it is unknown whether DM is associated with increased mortality or major complications during continuous-flow left ventricular assist device (CF-LVAD) support. METHODS AND RESULTS: We retrospectively reviewed 300 consecutive adults who received CF-LVADs at a single center in the years 2006-2013; 129 patients had DM before LVAD, as defined by American Diabetes Association criteria (HbA1c ≥6.5% and/or taking DM medications). Compared with the non-DM group, DMpatients were older, with a higher pre-LVAD body mass index, more ischemic heart failure etiology, and higher pre-LVAD creatinine. Ninety-three patients died on LVAD support, 43 with DM and 50 without DM (P = .4526). After control for 9 covariates in a Cox proportional hazards model, DM was unassociated with all-cause mortality (hazard ratio 0.883, 95% confidence interval 0.571-1.366; P = .5768). Diabetes was also unassociated with the adverse event end points of stroke/transient ischemic attack, intracerebral hemorrhage, pump thrombosis, and device-related infections. CONCLUSIONS:Diabetes is common in LVAD recipients (43% of the present cohort) but does not increase mortality or rates of major adverse events during CF-LVAD support.
Authors: Chinenye O Usoh; Saadia Sherazi; Barbara Szepietowska; Valentina Kutyifa; Scott McNitt; Anna Papernov; Meng Wang; Jeffrey D Alexis Journal: Ann Thorac Surg Date: 2018-03-22 Impact factor: 4.330
Authors: Evgenij V Potapov; Christiaan Antonides; Maria G Crespo-Leiro; Alain Combes; Gloria Färber; Margaret M Hannan; Marian Kukucka; Nicolaas de Jonge; Antonio Loforte; Lars H Lund; Paul Mohacsi; Michiel Morshuis; Ivan Netuka; Mustafa Özbaran; Federico Pappalardo; Anna Mara Scandroglio; Martin Schweiger; Steven Tsui; Daniel Zimpfer; Finn Gustafsson Journal: Eur J Cardiothorac Surg Date: 2019-08-01 Impact factor: 4.191
Authors: Finn Gustafsson; Binyamin Ben Avraham; Ovidiu Chioncel; Tal Hasin; Avishai Grupper; Aviv Shaul; Sanemn Nalbantgil; Yoav Hammer; Wilfried Mullens; Laurens F Tops; Jeremy Elliston; Steven Tsui; Davor Milicic; Johann Altenberger; Miriam Abuhazira; Stephan Winnik; Jacob Lavee; Massimo Francesco Piepoli; Lorrena Hill; Righab Hamdan; Arjang Ruhparwar; Stefan Anker; Marisa Generosa Crespo-Leiro; Andrew J S Coats; Gerasimos Filippatos; Marco Metra; Giuseppe Rosano; Petar Seferovic; Frank Ruschitzka; Stamatis Adamopoulos; Yaron Barac; Nicolaas De Jonge; Maria Frigerio; Eva Goncalvesova; Israel Gotsman; Osnat Itzhaki Ben Zadok; Piotr Ponikowski; Luciano Potena; Arsen Ristic; Tiny Jaarsma; Tuvia Ben Gal Journal: ESC Heart Fail Date: 2021-09-28